Alx Oncology Holdings
$ 1.62
-7.71%
14 Apr - close price
- Market Cap 230,314,000 USD
- Current Price $ 1.62
- High / Low $ 1.82 / 1.61
- Stock P/E N/A
- Book Value 0.48
- EPS -1.90
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.61 %
- ROE -1.46 %
- 52 Week High 2.66
- 52 Week Low 0.40
About
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company is headquartered in Burlingame, California.
Analyst Target Price
$4.60
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-07 | 2025-08-12 | 2025-05-07 | 2025-03-05 | 2024-11-11 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-13 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.3697 | -0.41 | -0.49 | -0.4773 | -0.4401 | -0.58 | -0.76 | -0.71 | -0.93 | -1.24 | -0.84 | -0.74 |
| Estimated EPS | -0.3525 | -0.37 | -0.43 | -0.309 | -0.3902 | -0.78 | -0.77 | -0.84 | -0.84 | -0.87 | -0.88 | -0.8 |
| Surprise | -0.0172 | -0.04 | -0.06 | -0.1683 | -0.0499 | 0.2 | 0.01 | 0.13 | -0.09 | -0.37 | 0.04 | 0.06 |
| Surprise Percentage | -4.8794% | -10.8108% | -13.9535% | -54.466% | -12.7883% | 25.641% | 1.2987% | 15.4762% | -10.7143% | -42.5287% | 4.5455% | 7.5% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.15 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALXO
2026-04-13 13:09:14
ALX Oncology Holdings (ALXO) has appointed Jeff Knight as Chief Development and Operating Officer on April 13, 2026. Knight brings extensive experience in clinical development and operations, and his compensation package includes a significant stock option grant, aligning his interests with shareholders. This strategic hire aims to strengthen the company's operational infrastructure as it advances its evorpacept and ALX2004 programs.
2026-04-13 13:09:14
ALX Oncology Holdings Inc. (Nasdaq: ALXO) has appointed Jeff Knight, M.P.H., as its new Chief Development and Operating Officer, effective April 13, 2026. Knight brings over 30 years of biopharmaceutical experience, including leadership roles at Crinetics Pharmaceuticals, Poseida Therapeutics, and Amgen, and is expected to strengthen ALX Oncology's development capabilities as the company anticipates significant milestones for its evorpacept and ALX2004 clinical programs.
2026-04-13 12:09:14
ALX Oncology (NASDAQ: ALXO) has appointed Jeff Knight as Chief Development and Operating Officer, effective April 13, 2026. Knight brings over 30 years of experience in biopharma and oncology, with a focus on clinical development, regulatory affairs, and operations. His appointment aims to strengthen ALX Oncology's development capabilities and supports upcoming catalysts for their evorpacept and ALX2004 clinical programs within the next 12-18 months.
2026-04-13 12:09:14
ALX Oncology Holdings Inc. has announced the appointment of Jeff Knight as Chief Development and Operating Officer, effective April 13, 2026. Mr. Knight brings over 30 years of biopharmaceutical industry experience, including significant expertise in clinical development, regulatory affairs, and operations, particularly in oncology. His appointment is expected to strengthen ALX Oncology's development capabilities as the company prepares for several key clinical milestones for its evorpacept and ALX2004 programs.
2026-04-13 12:09:14
ALX Oncology has announced the appointment of Jeff Knight as its new Chief Development and Operating Officer. This strategic hire aims to leverage Knight's extensive experience to advance the company's clinical development programs and operational efficiency. His background is expected to be instrumental in guiding ALX Oncology's future growth and pipeline progression.
2026-04-13 12:09:14
ALX Oncology Holdings Inc. has appointed Jeff Knight as its Chief Development and Operating Officer, effective April 13, 2026. Knight brings over three decades of biopharmaceutical experience, including roles at Crinetics, Poseida, and Amgen, and will be crucial in advancing ALX Oncology's clinical programs. His compensation includes an annual base salary of $565,000, a 40% target cash bonus, and stock options for 800,000 shares.
